Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT – Get Free Report)’s stock price rose 1% during trading on Thursday . The stock traded as high as $0.12 and last traded at $0.12. Approximately 42,939 shares traded hands during mid-day trading, a decline of 75% from the average daily volume of 173,214 shares. The stock had previously closed at $0.12.
Provectus Biopharmaceuticals Price Performance
The firm’s 50-day moving average price is $0.12 and its two-hundred day moving average price is $0.11.
Provectus Biopharmaceuticals Company Profile
Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.
Recommended Stories
- Five stocks we like better than Provectus Biopharmaceuticals
- How to Choose Top Rated Stocks
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- What is the Shanghai Stock Exchange Composite Index?
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- What Are the FAANG Stocks and Are They Good Investments?
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for Provectus Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
